PUBLISHER: The Business Research Company | PRODUCT CODE: 1946600
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946600
Neurostimulation devices are medical instruments designed to deliver electrical impulses to specific areas of the nervous system to modulate nerve activity. These devices are typically implanted or placed on the body to treat a range of neurological conditions. Neurostimulation works by altering or blocking pain signals or by stimulating specific neural pathways to restore function. These devices aim to enhance patients' quality of life by providing targeted, adjustable therapy tailored to individual needs.
The primary products in the neurostimulation devices market can be categorized into implantable devices and external devices. Implantable devices include cochlear implants, deep brain stimulation devices, spinal cord stimulation devices, vagus nerve stimulation devices, sacral nerve stimulation devices, and gastric electric stimulation devices. External devices encompass transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS). These devices are used in a variety of applications, including pain management, epilepsy, essential tremor, urinary and fecal incontinence, depression, dystonia, gastroparesis, and Parkinson's disease. They are employed by different healthcare facilities, such as hospitals, rehabilitation centers, and medical clinics.
Tariffs are impacting the neurostimulation devices market by increasing costs of imported electronic components, implantable materials, microcontrollers, sensors, and precision manufacturing equipment used in spinal cord, deep brain, and vagus nerve stimulators. North America and Europe are particularly affected due to reliance on global semiconductor and medical-grade component supply chains, while Asia-Pacific faces cost pressures in export-oriented device manufacturing. These tariffs are increasing production costs and device pricing, which may slow adoption in cost-sensitive healthcare settings. However, tariffs are also encouraging local manufacturing, regional sourcing of electronic components, and investments in domestic medical device production capabilities, strengthening long-term supply chain resilience.
The neurostimulation devices market research report is one of a series of new reports from The Business Research Company that provides neurostimulation devices market statistics, including neurostimulation devices industry global market size, regional shares, competitors with a neurostimulation devices market share, detailed neurostimulation devices market segments, market trends and opportunities, and any further data you may need to thrive in the neurostimulation devices industry. This neurostimulation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The neurostimulation devices market size has grown rapidly in recent years. It will grow from $6.86 billion in 2025 to $7.64 billion in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to increasing prevalence of chronic neurological disorders, wider clinical acceptance of implantable stimulation therapies, expansion of pain management treatment protocols, growing neurological disease diagnosis rates, availability of advanced implant technologies.
The neurostimulation devices market size is expected to see rapid growth in the next few years. It will grow to $12.03 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to increasing demand for personalized neuromodulation therapies, rising adoption of minimally invasive neurostimulation devices, growing investments in brain-computer interface research, expansion of home-based neuromodulation treatments, increasing regulatory approvals for novel stimulation indications. Major trends in the forecast period include increasing adoption of closed-loop neurostimulation systems, rising use of personalized neuromodulation therapies, growing integration of wireless and miniaturized implants, expansion of external non-invasive stimulation devices, enhanced focus on long-term therapy adjustability.
The growing demand within the healthcare industry is expected to drive the expansion of the neurostimulation devices market in the future. The healthcare industry is a broad and complex sector that includes various organizations, professionals, and institutions focused on delivering medical services, healthcare products, and improving overall health. Neurostimulation devices play a crucial role in this sector, especially in treating and managing neurological conditions and chronic pain. For example, in May 2023, a report from the Office for National Statistics, a UK-based government agency, revealed that healthcare spending in the UK increased by 5.6% from 2022 to 2023, compared to a 0.9% growth in 2022. In 2023, UK healthcare expenditure was approximately $322.152 billion (£292 billion). As a result, the expanding healthcare industry is contributing to the growth of the neurostimulation devices market.
Major companies operating in the neurostimulation devices market are concentrating on closed-loop spinal cord stimulation (SCS) systems to provide adaptive therapy that more closely corresponds to patients' everyday movements. Closed-loop SCS involves systems that detect physiological signals along the spinal cord and automatically modify stimulation in real time, rather than delivering fixed-output electrical pulses. For example, in April 2024, Medtronic plc, a US-based healthcare technology company, obtained FDA approval for its Inceptiv closed-loop rechargeable spinal cord stimulator. The device includes real-time sensing of biological signals, automatically regulates stimulus intensity, supports multiple waveforms (including its proprietary DTM therapy), and enables full-body 3T MRI access.
In November 2024, Medtronic plc, an Ireland-based medical device company, acquired Fortimedix Surgical for an undisclosed sum. Through this acquisition, Medtronic seeks to enhance its surgical and endoscopy portfolio, particularly to support its upcoming Hugo soft-tissue robotic system. Fortimedix is a Netherlands-based company that provides neurostimulation devices.
Major companies operating in the neurostimulation devices market are Medtronic plc, Cyberonics Inc., Boston Scientific Corporation, Abbott Laboratories, Nevro Corporation, Neuronetics Inc., NeuroPace Inc., NeuroSigma Inc., NDI Medical LLC, Synapse Biomedical Inc., MED-EL, LivaNova PLC, Aleva Neurotherapeutics, BrainsWay, Cortec Corporation, Endonovo Therapeutics Inc., Inspire Medical Systems Inc., The Magstim Company Limited, Mainstay Medical Limited, MicroTransponder Inc., MindMaze, NeuroMetrix, Nexeon MedSystems, Nuvectra, Saluda Medical, SPR Therapeutics Inc., Uro Medical Corporation
North America was the largest region in the global neurostimulation devices market in 2025. Asia-Pacific was the second-largest region in the neurostimulation devices market. The regions covered in the neurostimulation devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the neurostimulation devices market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
The neurostimulation devices market consists of sales of spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Neurostimulation Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses neurostimulation devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for neurostimulation devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurostimulation devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.